Here are 1-2 brief analogies to describe Rapport Therapeutics (RAPP):

• Like a CRISPR Therapeutics for the brain, using a novel platform to precisely target specific receptors for central nervous system (CNS) disorders.
• Imagine a precision oncology company, but for brain disorders, applying a unique platform to target specific neuronal receptors with high accuracy.

• RAP-219: An AMPA receptor negative allosteric modulator targeting TARPγ8, currently in Phase 2a for drug-resistant focal epilepsy, with planned trials for peripheral neuropathic pain and bipolar disorder.
• RAP-199: A second TARPγ8-targeted molecule with differentiated properties, expected to enter Phase 1 for undisclosed indications.
• a6 nAChR modulators: Discovery-stage drug candidates being developed for the treatment of chronic pain.
• a9a10 nAChR modulators: Discovery-stage drug candidates being developed for the treatment of hearing disorders.

Johnson & Johnson (JNJ)

The key risks for Rapport Therapeutics (RAPP) are primarily centered around the inherent challenges of a clinical-stage biopharmaceutical company, its specific technology platform, and its reliance on in-licensed intellectual property.

1. Failure of Clinical Trials and Inability to Obtain Regulatory Approval: As a clinical-stage company, Rapport Therapeutics' success is contingent upon the successful completion of clinical trials for its product candidates, particularly RAP-219 and RAP-199, and subsequent receipt of regulatory approvals. RAP-219, their most advanced candidate, is slated for Phase 2a trials in mid-2024, with topline results expected in mid-2025. Failure at any stage of clinical development (e.g., demonstrating safety or efficacy) or the inability to secure regulatory approval would severely impact the company's business and prospects.
2. Dependence on the RAP Technology Platform and Specific Targets: Rapport Therapeutics' entire pipeline and business strategy are built upon its proprietary Receptor Associated Protein (RAP) technology platform and deep expertise in RAP biology. The company's lead product candidates, RAP-219 and RAP-199, specifically target TARPγ8, which is associated with the neuronal AMPAR. If the underlying scientific premise of the RAP technology platform proves to be less effective than anticipated, or if the specific targets chosen (such as TARPγ8) do not yield the desired therapeutic outcomes or present unforeseen challenges, the development and commercialization of their entire pipeline could be jeopardized.
3. Reliance on In-Licensed Products and Associated Intellectual Property: A significant portion of Rapport Therapeutics' pipeline, including the advanced TARPγ8 products like RAP-219 and RAP-199, and certain nAChR products, originates from a license agreement with Janssen (the "Janssen License") entered into in August 2022. The company's ability to develop and commercialize these key product candidates is dependent on maintaining this license agreement and the validity and enforceability of the underlying intellectual property. Any issues arising with the Janssen License, such as its termination, disputes over its terms, or challenges to the intellectual property rights, could have a material adverse effect on Rapport Therapeutics.

Rapport Therapeutics (RAPP) focuses on developing small molecule medicines for central nervous system (CNS) disorders. The addressable markets for their main product candidates span several significant therapeutic areas:

• RAP-219 for Drug-Resistant Focal Epilepsy: The global intractable focal epilepsy market was valued at over US$2 billion in 2022 and is projected to reach USD 4.1 billion by 2033. More broadly, the global epilepsy drugs market is estimated to be valued at USD 10.88 billion in 2025 and is expected to reach USD 15.83 billion by 2032.
• RAP-219 for Peripheral Neuropathic Pain: The market size for peripheral neuropathic pain in the 7MM (United States, EU4, United Kingdom, and Japan) was approximately USD 12 billion in 2023. Globally, the neuropathic pain market size was valued at USD 6.39 billion in 2024 and is expected to reach USD 12.93 billion by 2032.
• RAP-219 for Bipolar Disorder: The global bipolar disorder treatment market size was valued at USD 5.7 billion in 2024 and is projected to grow to USD 8.2 billion by 2034. Other estimates place the global bipolar disorder treatment market size at USD 9.74 billion in 2025, projected to reach around USD 15.67 billion by 2034.
• a6 nAChR modulators for Chronic Pain: The global chronic pain market size is estimated to be valued at USD 77.30 billion in 2025 and is expected to reach USD 125.84 billion by 2032. Another report valued the global chronic pain treatment market at USD 78.0 billion in 2024, projected to reach USD 155.2 billion by 2035.
• a9a10 nAChR modulators for Hearing Disorders: The global hearing loss disease treatment market size was estimated at USD 11.54 billion in 2024 and is projected to reach USD 17.51 billion by 2030. More specifically for the drugs segment within this market, it is projected to reach USD 5.05 billion by 2034.

Here are 3-5 expected drivers of future revenue growth for Rapport Therapeutics (RAPP) over the next 2-3 years:

1. Successful advancement and positive clinical trial results for RAP-219 in focal epilepsy: Rapport Therapeutics intends to initiate a Phase 2a proof-of-concept trial for RAP-219 in adult patients with drug-resistant focal epilepsy in mid-2024, with topline results expected in mid-2025. Positive outcomes from this trial would significantly de-risk the company's most advanced product candidate, potentially attracting strategic partnerships, licensing agreements, or substantial future investment, which are key sources of revenue for clinical-stage biopharmaceutical companies.
2. Expansion of RAP-219 into new therapeutic indications: The company plans to initiate Phase 2a trials for RAP-219 in peripheral neuropathic pain in the second half of 2024 and in bipolar disorder in 2025. Successfully advancing RAP-219 into these additional indications would broaden the potential market and therapeutic utility of their lead asset, thereby increasing its overall value and attractiveness for future commercialization or partnership opportunities.
3. Progression of RAP-199 into Phase 1 clinical development: Rapport Therapeutics expects to initiate a Phase 1 trial for RAP-199, another TARPγ8 targeted molecule with differentiated properties, in the first half of 2025. Bringing a second product candidate into clinical development diversifies the company's pipeline and offers an additional potential source of future revenue through development milestones or licensing agreements.
4. Advancement of discovery-stage nicotinic acetylcholine receptor (nAChR) programs: Rapport Therapeutics is leveraging its RAP technology platform to develop modulators of a6 nAChRs for chronic pain and a9a10 nAChRs for hearing disorders. Significant progress in these discovery-stage programs could lead to early-stage partnerships or licensing agreements, providing non-dilutive funding or milestone payments as these programs advance through preclinical and potentially into clinical development within the 2-3 year timeframe.

Capital Allocation Decisions of Rapport Therapeutics (RAPP)

Share Issuance

• Rapport Therapeutics completed its Initial Public Offering (IPO) on June 6, 2024, pricing 8,000,000 shares of common stock at $17.00 per share, raising $136.0 million.
• Concurrently with the IPO, the company sold an additional 1,058,824 shares of common stock to existing stockholders in a private placement at the IPO price.
• Including the full exercise of the underwriters' option and the concurrent private placement, the gross proceeds from these offerings totaled approximately $174 million. An additional public offering in September 2025 yielded approximately $269.4 million in net proceeds.

Inbound Investments

• Rapport Therapeutics was formed in February 2022 with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC.
• In March 2026, Rapport entered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. for the development and commercialization of RAP-219 in Greater China.
• Under the Tenacia agreement, Rapport is eligible to receive an upfront payment of $20 million and up to approximately $308 million in potential development and commercialization milestones and other payments, along with tiered royalties on net sales.

Capital Expenditures

• Rapport Therapeutics expects its cash, cash equivalents, and short-term investments as of December 31, 2025, to fund its operating expenses and capital expenditure requirements into the second half of 2029.
• A primary focus for capital allocation is advancing the clinical development of its lead product candidate, RAP-219, into Phase 2a proof-of-concept trials for focal epilepsy, peripheral neuropathic pain, and bipolar disorder.
• The company also plans to allocate capital towards developing a long-acting injectable formulation of RAP-219 and advancing RAP-199 into Phase 1 trials, as well as other research and development activities.